Novavax Inc. [NVAX] shares are up more than 2730.34% this year and recently decreased -0.03% or -$3.13 to settle at $123.12. Analysts expect NVAX to shrink earnings at a 0.00% annual rate over the next 5 years. NVAX has a short ratio of 2.03. This implies that the market is currently less bearish on the outlook for NVAX.
On 30, November 2020, Novavax Announces COVID-19 Vaccine Clinical Development Progress. According to news published on Yahoo Finance, Pivotal Phase 3 trial in United Kingdom completes enrollment.
Analyst Birdseye View:
The most recent analyst activity for Novavax Inc. [NASDAQ:NVAX] stock was on August 05, 2020, when it was Upgrade with an Overweight rating from JP Morgan, which also raised its 12-month price target on the stock to $275. Before that, on August 06, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $290. On August 05, 2020, Ladenburg Thalmann Downgrade a Sell rating and boosted its price target on this stock to $105. On July 16, 2020, H.C. Wainwright Reiterated a Buy rating and increased its price target from $101 to $132. On July 08, 2020, Ladenburg Thalmann Downgrade a Neutral rating and increased its price target to $105. On June 29, 2020, H.C. Wainwright Reiterated a Buy rating and boosted its amount target on this stock to $101. On June 29, 2020, B. Riley FBR Reiterated a Buy rating and boosted its target amount on this stock from $74 to $106. JP Morgan elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $3.65 and a peak of $189.40. Right now, the middling Wall Street analyst 12-month amount mark is $211.00. At the most recent market close, shares of Novavax Inc. [NASDAQ:NVAX] were valued at $123.12. According to the average price forecast, investors can expect a potential return of 11.75%.
Novavax Inc. [NASDAQ:NVAX] most recently reported quarterly sales of 157.02 billion, which represented growth of 6163.40%. This publicly-traded organization’s revenue is $113,103 per employee, while its income is -$804,206 per employee.
The Principal structure of this organization shows its whole liability to whole principal at 227.53 and the whole liability to whole assets at 191.88. It shows enduring liability to the whole principal at 226.67 and enduring liability to assets at 1.91 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 120.36 points at 1st support level, the second support level is making up to 117.61. But as of 1st resistance point, this stock is sitting at 128.26 and at 133.41 for 2nd resistance point.
Novavax Inc. [NVAX] reported its earnings at -$3.21 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $1.73/share signifying the difference of -4.94 and -285.50% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.3 calling estimates for -$0.42/share with the difference of 0.12 depicting the surprise of 28.60%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Novavax Inc. [NASDAQ:NVAX] is 2.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.17. Now if looking for a valuation of this stock’s amount to sales ratio it’s 5.14.
The most recent insider trade was by Erck Stanley C, President and CEO, and it was the sale of 52316.0 shares on Nov 16. Erck Stanley C, the President and CEO, completed a sale of 2.0 shares on Oct 01. On Sep 30, Trizzino John, EVP, CBO and CFO, completed a sale of 2250.0 shares.